|
www.aurobindo.com |
|
|
|
|
Aurobindo receives USFDA Approval
for Cefpodoxime proxetil Tablets |
|
|
Aurobindo Pharma Limited is
pleased to announce that the USFDA has approved
one more from its cephalosporin stable and again
from its third generation breed. Cefpodoxime
proxetil Tablets in the strengths of 100mg and
200mg has been approved. This is the 7th
cephalosporin approval for Aurobindo. With this
the company consolidates itself further in
cephalosporin market. Cefpodoxime is the generic
version of Pharmacia Upjohn’s Vantin. |
|
Cefpodoxime Proxetil is mostly
used to treat Acute otitis media, community
acquired Pneumoniae, Uncomlicated Urinary tract
infections and also skin infections. |
|
Aurobindo is the proven leader in
this segment/product range in several markets in
the world. This would be a niche opportunity for
the company as there are limited number of
players in the segment. |
|
USFDA has also confirmed its
approval for
Cefpodoxime proxetil for oral
suspension in the strengths of 50mg/5ml and
100mg/5ml. |
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma Limited
(www.aurobindo.com), headquartered at Hyderabad,
India, manufactures generic pharmaceuticals and
active pharmaceutical ingredients. The company
has received approvals for most of the targeted
API and formulation facilities from leading
regulatory agencies like US FDA, UK MHRA, WHO,
Health Canada, MCC South Africa. The company’s
robust product portfolio is spread over 6 major
therapeutic/product areas encompassing
Antibiotics, Anti-Retrovirals, CVS, CNS,
Gastroenterologicals, and Anti-Allergics. The
formulation portfolio is built on six technology
platforms such as immediate release generics,
SR/CR generics, Orally disintegrating/Mouth
dissolving generics, Combination products,
Sterile/Lyophilized generics and Liquids/Dry
syrups.
Aurobindo has filed over 100 DMFs
and 79 ANDAs for the USA market alone in
addition to filings in other countries. The pace
of filings is matched by rapid product approvals
from various markets. Till date Aurobindo
received 40 ANDA approvals (both final and
tentative) from US alone. Aurobindo operates in
over 100 countries and markets over 180 APIs and
250 formulations |
For further information,
please contact:
Investor Relations
Aurobindo Pharma Limited
Plot # 2, Maitri Vihar | Ameerpet
Hyderabad - 500 038 |India
Phone (Board): +91 40 6672 5000
Mobile 0 98486 67906
Email : ir@aurobindo.com |
|
|
|
|
|
|
|
|
|
PRESS
ROOM
